DEVELOPING
Importance
60
Trust
71
Urgency
65
COMMERCIAL
Recon: FDA to reconsider Atara, Pierre Fabre drug after surprise rejection; Amazon to stock Ozempic at US kiosks - RAPS.org
Amazon will sell semaglutide (Ozempic, a weight-loss drug) at U.S. kiosks. The FDA is reviewing a rejected drug from Atara and Pierre Fabre, though that drug is not a peptide.
Analysis
Amazon kiosks could make it easier for people to get Ozempic. That gives Novo a new way to reach buyers in the US.
- Amazon plans to stock Ozempic at US kiosks
- FDA will reconsider an Atara and Pierre Fabre drug after a surprise rejection
Semaglutide News1mo
Read